Biotricity Stock Fundamentals
| BTCY Stock | USD 1.39 0.06 4.14% |
Biotricity fundamentals help investors to digest information that contributes to Biotricity's financial success or failures. It also enables traders to predict the movement of Biotricity Stock. The fundamental analysis module provides a way to measure Biotricity's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotricity stock.
At this time, Biotricity's Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 30.2 M in 2024, whereas Depreciation And Amortization is likely to drop 6,504 in 2024. Biotricity | Select Account or Indicator |
Biotricity Company Operating Margin Analysis
Biotricity's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Biotricity Operating Margin | (0.43) % |
Most of Biotricity's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotricity is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Biotricity Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Biotricity has an Operating Margin of -0.4311%. This is 98.77% lower than that of the Health Care Equipment & Supplies sector and 98.9% lower than that of the Health Care industry. The operating margin for all United States stocks is 92.18% lower than that of the firm.
Biotricity Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotricity's current stock value. Our valuation model uses many indicators to compare Biotricity value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotricity competition to find correlations between indicators driving Biotricity's intrinsic value. More Info.Biotricity is rated third in return on equity category among related companies. It is rated third in return on asset category among related companies . At this time, Biotricity's Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Biotricity by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biotricity's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotricity's earnings, one of the primary drivers of an investment's value.Biotricity Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotricity's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotricity could also be used in its relative valuation, which is a method of valuing Biotricity by comparing valuation metrics of similar companies.Biotricity is currently under evaluation in operating margin category among related companies.
Biotricity Current Valuation Drivers
We derive many important indicators used in calculating different scores of Biotricity from analyzing Biotricity's financial statements. These drivers represent accounts that assess Biotricity's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Biotricity's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 5.1M | 5.8M | 15.0M | 17.2M | 4.0M | 11.8M | |
| Enterprise Value | 5.9M | 7.2M | 17.5M | 20.5M | 23.0M | 11.4M |
Biotricity Fundamentals
| Return On Equity | -41.01 | ||||
| Return On Asset | -0.95 | ||||
| Profit Margin | (1.25) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 38.1 M | ||||
| Shares Outstanding | 9.31 M | ||||
| Shares Owned By Insiders | 14.81 % | ||||
| Shares Owned By Institutions | 4.70 % | ||||
| Number Of Shares Shorted | 358.44 K | ||||
| Price To Earning | (6.70) X | ||||
| Price To Book | 33.02 X | ||||
| Price To Sales | 0.94 X | ||||
| Revenue | 9.64 M | ||||
| Gross Profit | 4.57 M | ||||
| EBITDA | (15.59 M) | ||||
| Net Income | (18.66 M) | ||||
| Cash And Equivalents | 2.89 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 19.55 M | ||||
| Debt To Equity | 6.45 % | ||||
| Current Ratio | 1.54 X | ||||
| Book Value Per Share | (2.95) X | ||||
| Cash Flow From Operations | (13.55 M) | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | (1.75) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 55 | ||||
| Beta | 1.54 | ||||
| Market Capitalization | 13.26 M | ||||
| Total Asset | 6.51 M | ||||
| Retained Earnings | (112.57 M) | ||||
| Working Capital | (6.44 M) | ||||
| Current Asset | 11 K | ||||
| Current Liabilities | 303 K | ||||
| Net Asset | 6.51 M |
About Biotricity Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotricity's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotricity using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotricity based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.8 M | 1.9 M | |
| Total Revenue | 11.1 M | 11.6 M | |
| Cost Of Revenue | 4.8 M | 5.1 M | |
| Stock Based Compensation To Revenue | 0.08 | 0.07 | |
| Sales General And Administrative To Revenue | 2.10 | 2.00 | |
| Research And Ddevelopement To Revenue | 0.39 | 0.37 | |
| Capex To Revenue | (0) | (0) | |
| Revenue Per Share | 1.00 | 1.05 | |
| Ebit Per Revenue | (1.46) | (1.53) |
Pair Trading with Biotricity
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biotricity position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biotricity will appreciate offsetting losses from the drop in the long position's value.Moving against Biotricity Stock
| 0.68 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
| 0.67 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
| 0.57 | NAOV | NanoVibronix | PairCorr |
| 0.54 | SINT | SINTX Technologies | PairCorr |
| 0.49 | HSTM | HealthStream | PairCorr |
The ability to find closely correlated positions to Biotricity could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biotricity when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biotricity - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biotricity to buy it.
The correlation of Biotricity is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biotricity moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biotricity moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biotricity can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Biotricity Piotroski F Score and Biotricity Altman Z Score analysis. For more information on how to buy Biotricity Stock please use our How to Invest in Biotricity guide.Note that the Biotricity information on this page should be used as a complementary analysis to other Biotricity's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Biotricity Stock analysis
When running Biotricity's price analysis, check to measure Biotricity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotricity is operating at the current time. Most of Biotricity's value examination focuses on studying past and present price action to predict the probability of Biotricity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotricity's price. Additionally, you may evaluate how the addition of Biotricity to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Biotricity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biotricity. If investors know Biotricity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biotricity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 1.319 | Quarterly Revenue Growth 0.209 | Return On Assets (0.95) | Return On Equity (41.01) |
The market value of Biotricity is measured differently than its book value, which is the value of Biotricity that is recorded on the company's balance sheet. Investors also form their own opinion of Biotricity's value that differs from its market value or its book value, called intrinsic value, which is Biotricity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biotricity's market value can be influenced by many factors that don't directly affect Biotricity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biotricity's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biotricity is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biotricity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.